24 days
Time to First Decision

Uro, Volume 4, Issue 1

2024 March - 2 articles

Cover Story: This prospective pilot study explored the potential of the innate immune system’s response to cancer-related immuno-stimulants as a predictive biomarker for Immune Checkpoint Inhibitor (ICI) effectiveness, using pembrolizumab-treated patients with metastatic urothelial tract cancer (mUTC) as the study population. We included ten mUTC patients and assessed their innate immune responses before the first and second pembrolizumab cycles with the TruCulture^® immunoassay. We also executed survival analysis and compared cytokine release. Our small study identified distinct immune response patterns following pembrolizumab’s first cycle in mUTC patients, hypothesizing the potential of an increased R848-induced IFNα response for improved survival outcomes. Further confirmatory studies are in progress. View this paper

Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
You may sign up for email alerts to receive table of contents of newly released issues.
PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.

Articles (2)

Select all

Article

1,784 Views

11 Pages

Patient Factors and Their Effect on Operating Room Time for Urologic Procedures

Wei-Shin Lu,
Ali Zia,
Nagalakshmi Nadiminty,
Barbara Saltzman,
Andrew B. Casabianca and
Puneet Sindhwani

Uro2024, 4(1), 12-22;https://doi.org/10.3390/uro4010002

4 March 2024

Introduction: We examined three patient characteristics: body mass index (BMI), the American Society of Anesthesiologists (ASA) status, and pre-admission testing (PAT), and their effect on total operating room (OR) time for six urologic procedures, i...

Full Article

Article

2,670 Views

11 Pages

An Exploratory Study of Early Immune Response Markers for Pembrolizumab in Urothelial Tract Cancer

Dag Rune Stormoen,
Lise Høj Omland,
Kent William Mouw,
Zoltan Szallasi,
Sisse Rye Ostrowski,
Susanne Dam Nielsen and
Helle Pappot

Uro2024, 4(1), 1-11;https://doi.org/10.3390/uro4010001

12 January 2024

Background: This prospective pilot study explored the potential of the innate immune system’s response to cancer-related immuno-stimulants as a predictive biomarker for Immune Checkpoint Inhibitor (ICI) effectiveness, using pembrolizumab-treate...

Full Article

Get Alerted

Add your email address to receive forthcoming issues of this journal.

Uro - ISSN 2673-4397

Imprint

Download Flyer